Skip to main content

. 1979 Sep;190(3):366–372. doi: 10.1097/00000658-197909000-00012

Specific active immunotherapy for melanoma.

H F Seigler, E Cox, F Mutzner, L Shepherd, E Nicholson, W W Shingleton

PMCID: PMC1344672 PMID: 485611

366

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bodurtha A. J., Chee D. O., Laucius J. F., Mastrangelo M. J., Prehn R. T. Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res. 1975 Jan;35(1):189–193. [PubMed] [Google Scholar]
Goulmy E., Termijtelen A., Bradley B. A., van Rood J. J. HLA restriction of non-HLA--A, --B, --C and --D cell mediated lympholysis (CML). Tissue Antigens. 1976 Nov;8(5):317–326. doi: 10.1111/j.1399-0039.1976.tb00583.x. [DOI] [PubMed] [Google Scholar]
Koprowski H., Steplewski Z., Herlyn D., Herlyn M. Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3405–3409. doi: 10.1073/pnas.75.7.3405. [DOI] [PMC free article] [PubMed] [Google Scholar]
Lewis M. G., McCloy E., Blake J. The significance of humoral antibodies in the localization of human malignant melanoma. Br J Surg. 1973 Jun;60(6):443–446. doi: 10.1002/bjs.1800600607. [DOI] [PubMed] [Google Scholar]
Winchester R. J., Ross G. D., Jarowski C. I., Wang C. Y., Halper J., Broxmeyer H. E. Expression of Ia-like antigen molecules on human granulocytes during early phases of differentiation. Proc Natl Acad Sci U S A. 1977 Sep;74(9):4012–4016. doi: 10.1073/pnas.74.9.4012. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES